Testing mismatch repair proteins versus microsatellite instability in colorectal carcinoma

doi:10.3877/cma.j.issn.2095-3224.2016.05.006

Abstract

Abstract:

Objective

Immunohistochemical (IHC) staining for mismatch repair (MMR) proteins and PCR-based detection for microsatellite status are routinely performed on colorectal carcinoma (CRC) surgical samples. However, the concordance of the two detections, which is related to the quality control of our molecular pathology laboratory, is unknown so far. So the main aim of this study is to compare the differences between the two analyses and to improve our work.

Methods

IHC analyzed the expression of MLH1, PMS2, MSH2 and MSH6 which was performed on 368 cases of formalin-fixed paraffin-embedded (FFPE) CRC tissues. If any one protein is negative in all of cancer cells but positive in normal colorectal mucosa, the IHC staining was reported as mismatch repair defective (dMMR). If the four MMR proteins are expressed in the nucleus of one or more cancer cells, the IHC result was interpreted as mismatch repair proficient (pMMR). All of the 37 cases of dMMR and selected 28 cases of pMMR were tested by PCR-based MSI analysis. Paired normal and cancer DNA samples isolated from the FFPE tissues were tested for MSI using Bethesda recommended 5 markers (BAT25, BAT26, D2S123, D5S346, D17S250). At last the results of IHC and PCR were compared and their concordance were analyzed.

Results

IHC analyses were performed on 368 cases of CRC, among which 37 cases were dMMR and 331 cases were pMMR. After excluding 2 cases from the 37 samples, the remained 35 samples were tested for MSI, among which 32 samples were high-level microsatellite instability (MSI-H) and 3 samples were microsatellite stable (MSS). In addition, 28 cases of pMMR samples were selected to be tested by PCR for MSI, among which 27 cases were MSS but one case was MSI-H. The sensitivity and specificity of immunohistochemistry was 97.0% and 90.0%, separately, the sensitivity and specificity of PCR was 91.4% and 96.4%, separately, and the total concordance of the two detections achieved 93.7%. The most common original site of dMMR CRC was right hemicolon (occupying 48.6%), and the most common pathological features included mucous adenocarcinoma, poor differentiated adenocarcinoma with lymphocytes infiltration, and pathologic TNM stage Ⅱ and stage Ⅲ.

Conclusions

The total concordance of the immunohistochemistry for MMR proteins and PCR-based MSI testing achieved 93.7%, and the former is an economic and quick screening method which is deserved to be popularized in China. Moreover, we have to emphasize the important role of intra and external laboratory quality control of the two methods and then to improve the process, so as to increase the testing accuracy.

Key words: Colorectal neoplasms, Immunohistochemistry, Microsatellite instability, Mismatch repair proteins

Qiongrong Chen, Manxiang Wang, Fang Guo, Jing Kuang, Na Fang, Mingwei Wang, Su Jin, De Wu, Yunte Deng, Shaozhong Wei. Testing mismatch repair proteins versus microsatellite instability in colorectal carcinoma[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(05): 398-404.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2016.05.006

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2016/V05/I05/398

Figures/Tables 4

References 34

[1]	Hamilton SR,Bosman FT,Boffetta P, et al. Carcinoma of the colon and rectum. In: Bosman FT,Carneiro F,Hruban RH,Theise ND, eds. WHO Classification of Tumours of the Digestive System[M]. 4th Edition. Lyon: IARC Press, 2010: 134-146.
[2]	Lindor NM,Burgart LJ,Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors[J]. J Clin Oncol, 2002, 20(4): 1043-1048.
[3]	Moreira L,Balaguer F,Lindor N, et al. Identification of Lynch syndrome among patients with colorectal cancer[J]. JAMA, 2012, 308(15): 1555-1565.
[4]	Hampel H,Frankel WL,Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer)[J]. N Engl J Med, 2005, 352(18): 1851-1860.
[5]	Guastadisegni C,Colafranceschi M,Ottini L, et al. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data[J]. Eur J Cancer, 2010, 46(15): 2788-2798.
[6]	Webber EM,Kauffman TL,O'Connor E, et al. Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5-FU based chemotherapy[J]. BMC Cancer, 2015, 15: 156.
[7]	Le DT,Uram JN,Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency[J]. N Engl J Med, 2015, 372(26): 2509-2520.
[8]	秦云,梁莉萍,郑兴征,等.免疫组织化学法检测结直肠癌四种DNA错配修复蛋白表达缺失对判断肿瘤微卫星状态的价值[J]. 中华病理学杂志, 2015, 44(10): 704-708.
[9]	石迎雪,郑杰. 系统筛查微卫星不稳定性结直肠癌的意义和策略[J]. 中华病理学杂志, 2015, 44(1): 9-14.
[10]	Overbeek LI,Ligtenberg MJ,Willems RW, et al. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting[J]. Am J Surg Pathol, 2008, 32(8): 1246-1251.
[11]	Umar A,Boland CR,Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability[J]. J Natl Cancer Inst, 2004, 96(4): 261-268.
[12]	Niessen RC,Berends MJ,Wu Y, et al. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer[J]. Gut, 2006, 55(12): 1781-1788.
[13]	Edge SB,Byrd SR,Compton CC, et al. AJCC Cancer Staging Manual, 7th edition[M]. New York: Springer-Verlag, 2010: 143-164.
[14]	Christensen M,Katballe N,Wikman F, et al. Antibody-based screening for hereditary nonpolyposis colorectal carcinoma compared with microsatellite analysis and sequencing[J]. Cancer, 2002, 95(11): 2422-2430.
[15]	Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry[J]. J Mol Diagn, 2008, 10(4): 293-300.
[16]	Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing[J]. J Mol Diagn, 2008, 10(4): 301-307.
[17]	Sargent DJ,Marsoni S,Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer[J]. J Clin Oncol, 2010, 28(20): 3219-3226.
[18]	Ye JX,Liu Y,Qin Y, et al. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients[J]. World J Gastroenterol, 2015, 21(5): 1595-1605.
[19]	Jenkins MA,Hayashi S,O’Shea AM, et al. Pathology Features in Bethesda Guidelines Predict Colorectal Cancer Microsatellite Instability: A Population-Based Study[J]. Gastroenterology, 2007, 133(1): 48-56.
[20]	张玥,石菊芳,黄慧, 等.中国人群结直肠癌疾病负担分析[J]. 中华流行病学杂志, 2015, 36(7): 709-714.
[21]	Karahan B,Argon A,Yıldırım M, et al. Relationship between MLH-1, MSH-2, PMS-2, MSH-6 expression and clinicopathological features in colorectal cancer[J]. Int J Clin Exp Pathol, 2015, 8(4): 4044-4053.
[22]	Angelova M,Charoentong P,Hackl H, et al. The colorectal cancer immune paradox revisited[J]. Oncoimmunology, 2015, 5(2): e1078058.
[23]	Parcesepe P,Giordano G,Laudanna C, et al. Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer[J]. Gastroenterol Res Pract, 2016: 6261721.
[24]	Joost P,Veurink N,Holck S, et al. Heterogenous mismatch-repair status in colorectal cancer[J]. Diagn Pathol, 2014, 9: 126.
[25]	Engel KB,Moore HM. Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue[J]. Arch Pathol Lab Med, 2011, 135(5): 537-543.
[26]	Cicek MS,Lindor NM,Gallinger S, et al. Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population-and clinic-based colorectal tumors results from the Colon Cancer Family Registry[J]. J Mol Diagn, 2011, 13(3): 271-281.
[27]	Umar A,Risinger JI,Glaab WE, et al. Functional overlap in mismatch repair by human MSH3 and MSH6[J]. Genetics, 1998, 1484(): 1637-1646.
[28]	Pino MS,Chung DC. Microsatellite instability in the management of colorectal cancer[J]. Expert Rev Gastroenterol Hepatol, 2011, 5(3): 385-399.
[29]	Rigau V,Sebbagh N,Olschwang S, et al. Microsatellite instability in colorectal carcinoma. The comparison of immunohistochemistry and molecular biology suggests a role for hMSH6[correction of hMLH6] immunostaining[J]. Arch Pathol Lab Med, 2003, 127(6): 694-700.
[30]	Graham RP,Kerr SE,Butz ML, et al. Heterogenous MSH6 loss is a result of microsatellite instability within MSH6 and occurs in sporadic and hereditary colorectal and endometrial carcinomas[J]. Am J Surg Pathol, 2015, 39(10): 1370-1376.
[31]	Patil DT,Bronner MP,Portier BP, et al. A five-marker panel in a multiplex PCR accurately detects microsatellite instability-high colorectal tumors without control DNA[J]. Diagn Mol Pathol, 2012, 21(3): 127-133.
[32]	Bacher JW,Flanagan LA,Smalley RL, et al. Development of a fluorescent multiplex assay for detection of MSI-High tumors[J]. Dis Markers, 2004, 20(4-5): 237-250.
[33]	Southey MC,Jenkins MA,Mead L, et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer[J]. J Clin Oncol, 2005, 23(27): 6524-6532.
[34]	Müller A,Giuffre G,Edmonston TB, et al. Challenges and pitfalls in HNPCC screening by microsatellite analysis and immunohistochemistry[J]. J Mol Diagn, 2004, 6(4):308-315.

Please choose a citation manager

Content to export